- Home
- MCRB vs BMN Comparison
MCRB vs BMN Comparison
Compare MCRB & BMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- BMN
- Stock Information
- Founded
- MCRB 2010
- BMN 2020
- Country
- MCRB United States
- BMN United States
- Employees
- MCRB N/A
- BMN 19800
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- BMN Trusts Except Educational Religious and Charitable
- Sector
- MCRB Health Care
- BMN Finance
- Exchange
- MCRB Nasdaq
- BMN Nasdaq
- Market Cap
- MCRB 141.9M
- BMN 156.9M
- IPO Year
- MCRB 2015
- BMN N/A
- Fundamental
- Price
- MCRB $0.72
- BMN $25.15
- Analyst Decision
- MCRB Hold
- BMN
- Analyst Count
- MCRB 5
- BMN 0
- Target Price
- MCRB $4.00
- BMN N/A
- AVG Volume (30 Days)
- MCRB 840.7K
- BMN 29.9K
- Earning Date
- MCRB 03-13-2025
- BMN 01-01-0001
- Dividend Yield
- MCRB N/A
- BMN 4.66%
- EPS Growth
- MCRB N/A
- BMN N/A
- EPS
- MCRB 0.00
- BMN N/A
- Revenue
- MCRB N/A
- BMN N/A
- Revenue This Year
- MCRB N/A
- BMN N/A
- Revenue Next Year
- MCRB N/A
- BMN N/A
- P/E Ratio
- MCRB $824.00
- BMN N/A
- Revenue Growth
- MCRB N/A
- BMN N/A
- 52 Week Low
- MCRB $0.54
- BMN $21.51
- 52 Week High
- MCRB $1.53
- BMN $25.59
- Technical
- Relative Strength Index (RSI)
- MCRB 46.92
- BMN 43.86
- Support Level
- MCRB $0.69
- BMN $25.01
- Resistance Level
- MCRB $0.76
- BMN $25.36
- Average True Range (ATR)
- MCRB 0.05
- BMN 0.22
- MACD
- MCRB 0.00
- BMN -0.00
- Stochastic Oscillator
- MCRB 53.55
- BMN 33.67
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.